
Lupin stock surges on robust sales in March quarter
In the March quarter, the company’s profit before tax stood at ₹235.9 crore as against the net loss of ₹517.9 crore in the same period last year.
In the March quarter, the company’s profit before tax stood at ₹235.9 crore as against the net loss of ₹517.9 crore in the same period last year.
The U.S. drug regulator has issued Form 483 with ten observations for Lupin’s Pithampur unit-2 manufacturing facility.
The pharma major has launched a novel fixed-dose triple drug combination ‘DIFIZMA’ to treat inadequately controlled asthma.
Lupin Pharmaceuticals Inc., the U.S. arm of the drug major, is voluntarily recalling four lots of Quinapril Tablets due to the presence of nitrosamine impurity.
India's healthcare firms spent $4.32 billion during January to June of 2022 on mergers and acquisitions, compared to $2.02 billion in the same period last year
Lupin has received U.S. FDA approval for Mirabegron Extended-Release Tablets used for the treatment of overactive bladder.
The Sensex and Nifty are set to open higher on the first day of September F&O contracts, tracking firm cues from global equities and positive trends on SGX Nifty Futures.
The Sensex and Nifty are poised for a negative opening on Friday, following mixed cues from global peers and weak trends across SGX Nifty Futures.
The revenue growth of about 16 leading Indian pharmaceutical companies is estimated to moderate to 6-7% in FY23, says ICRA.
The Sensex and Nifty are set to bell the day in negative terrain, tracking weak cues from global peers and similar trends on the SGX Nifty futures.